A dry stable probiotic composition is provided. The composition comprises one or more viable probiotic microorganisms, one or more hydrolyzed proteins, one or more disaccharides, one or more oligosaccharides, and one or more polysaccharides, but not trehalose. The composition has viability of at least 1×10.sup.10 CFU/g, and a viability loss of less than 1 log unit/g after one month at a temperature of 40° C. and a relative humidity of 33%. Also provided are methods for preparing the dry stable probiotic composition.

The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.

The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.

The present disclosure generally relates to methods of preparing protein hydrolysates for use in pediatric nutritional compositions. Specifically, alpha-, beta- and/or kappa casein enriched casein, acid casein or caseinates can be hydrolyzed with proteases such as trypsin (trypsin-like), chymotrypsin (chymotrypsin-like), pepsin and/or plasmin to produce a hydrolysate that is close to the peptide composition of human breast milk.

Methods of treating or preventing gestational diabetes mellitus (GDM) and/or treating or preventing one or more GDM-associated risks or one or more sequelae of GDM by administering one or more polar lipids, in addition to uses, compositions, and medicaments comprising one or more polar lipids to treat or prevent gestational diabetes mellitus and/or treat or prevent one or more GDM-associated risks or one or more sequelae of GDM.

Methods of treating or preventing gestational diabetes mellitus (GDM) and/or treating or preventing one or more GDM-associated risks or one or more sequelae of GDM by administering one or more polar lipids, in addition to uses, compositions, and medicaments comprising one or more polar lipids to treat or prevent gestational diabetes mellitus and/or treat or prevent one or more GDM-associated risks or one or more sequelae of GDM.

Disclosed are Lactobacillus rhamnosus strain 753 and uses thereof, a silage additive and silage. Lactobacillus rhamnosus strain 753 is deposited in China General Microbiological Culture Collection Center with an accession number of CGMCC 18233. Lactobacillus rhamnosus strain 753 can improve the quality of silage in a high-temperature and high-humidity region, and the silage processed by Lactobacillus rhamnosus strain 753 has good stability and low pH, low aflatoxin B1 content and less dry matter loss. In addition, secondary fermentation can be avoided in the silage processed by Lactobacillus rhamnosus strain 753 when a silo or bale for silage is opened.

The present invention provides a composition for promoting glucolipid metabolism, and a preparation and an application thereof, and relates to the technical field of probiotics. The composition of the present invention includes probiotics and inulin; the probiotics include Bifidobacterium longum, Bifidobacterium breve, Lactobacillus gasseri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus cripatus, Lactobacillus plantarum, Lactobacillus fermentum, and Lactobacillus casei. In the composition of the present invention, the nine strains synergize with each other, which function as a regulator of glucolipid metabolism, improve sensitivity to insulin receptor in the body, and relieve insulin resistance when reconstituted with inulin. The composition has some effects on improving serum total cholesterol and triglyceride, islet -cell function, and type 2 diabetes mellitus.

The present invention provides a composition for promoting glucolipid metabolism, and a preparation and an application thereof, and relates to the technical field of probiotics. The composition of the present invention includes probiotics and inulin; the probiotics include Bifidobacterium longum, Bifidobacterium breve, Lactobacillus gasseri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus cripatus, Lactobacillus plantarum, Lactobacillus fermentum, and Lactobacillus casei. In the composition of the present invention, the nine strains synergize with each other, which function as a regulator of glucolipid metabolism, improve sensitivity to insulin receptor in the body, and relieve insulin resistance when reconstituted with inulin. The composition has some effects on improving serum total cholesterol and triglyceride, islet -cell function, and type 2 diabetes mellitus.

A microbial fermentation composition is prepared through after extracting and enzymolyzing selected Edible and medicinal fungi Agaricus blazei, Lentinus edodes, Flammulina velutipes and ginseng of reinforcing vital energy, adding trace elements selenium, zinc and molybdenum, and fermenting and transforming by probiotics. It is demonstrated through experiments of in vitro inhibition of HepGII cells (a liver cancer cell) and Hela cells (a cervical cancer cell) that the fermentation composition formed by probiotic fermentation has significant inhibitory effect on the proliferation of tumor cells. Compared with the non-fermented composition, the fermentation composition has a significantly enhanced inhibitory effect on experimental tumor cells and the difference is significant. The inhibitory effect of the fermentation composition on experimental tumor cells increases with the increase of the concentration.